Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 12:10.1002/JLB.3MIR0817-337R.
doi: 10.1002/JLB.3MIR0817-337R. Online ahead of print.

Negative regulators that mediate ocular immune privilege

Affiliations
Review

Negative regulators that mediate ocular immune privilege

Andrew W Taylor et al. J Leukoc Biol. .

Abstract

The ocular microenvironment has adapted several negative regulators of inflammation to maintain immune privilege and health of the visual axis. Several constitutively produced negative regulators within the eye TGF-β2, α-melanocyte stimulating hormone (α-MSH), Fas ligand (FasL), and PD-L1 standout because of their capacity to influence multiple pathways of inflammation, and that they are part of promoting immune tolerance. These regulators demonstrate the capacity of immune privilege to prevent the activation of inflammation, and to suppress activation of effector immune cells even under conditions of ocular inflammation induced by endotoxin and autoimmune disease. In addition, these negative regulators promote and expand immune cells that mediate regulatory and tolerogenic immunity. This in turn makes the immune cells themselves negative regulators of inflammation. This provides for a greater understanding of immune privilege in that it includes both molecular and cellular negative regulators of inflammation. This would mean that potentially new approaches to the treatment of autoimmune disease can be developed through the use of molecules and cells as negative regulators of inflammation.

Keywords: Immunosuppression; anti-inflammatory; eye; neuropeptides; regulatory T cells; suppressor macrophages; tolerance.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES

The authors declare no conflicts of interest.

References

    1. Medawar P Immunity to homologous grafted skin. III. the fate of skinhomografts transplanted to the brain to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58–69. - PMC - PubMed
    1. Barker CF, Billingham RE. Immunologically privileged sites. Adv Immunol. 1977;25:1–54. - PubMed
    1. Taylor AW.Ocular immune privilege. Eye (Lond). 2009;23:1885–1889. - PMC - PubMed
    1. Taylor AW, Kaplan HJ. Ocular immune privilege in the year 2010: ocular immune privilege and uveitis. Ocul Immunol Inflamm. 2010;18:488–492. - PMC - PubMed
    1. Caspi RR. Understanding autoimmunity in the eye: from animal models to novel therapies. Discov Med. 2014;17:155–162. - PMC - PubMed